TRT(SH:600085) 2 1 Shi Ji Jing Ji Bao Dao·2025-12-31 08:01Core Viewpoint - The Beijing Tongrentang Group has initiated preliminary measures in response to the Antarctic krill oil fraud incident, including the resignation of the general manager of Sichuan Health and the suspension of other related management personnel, while also recalling affected products and blocking their circulation channels [1][4]. Group 1: Company Actions and Responses - The Beijing Tongrentang Group has ordered the resignation of Li Shengyi from the position of general manager of Sichuan Health and suspended all other related management personnel [1][4]. - The group is actively promoting the recall of affected products and has issued statements to major e-commerce platforms to block the circulation of these products [1][4]. - A working group led by senior executives has been established to take over the management of Sichuan Health, and the group is cooperating with local authorities in the investigation [4]. Group 2: Industry Implications - The incident has raised concerns about the integrity of health products and the brand's long-standing social credibility, prompting calls for stronger regulatory oversight and social supervision in the health food industry [1][5]. - The Antarctic krill, previously seen mainly as a nutritional supplement, is gaining attention for its significant medicinal value, with ongoing research into its applications in various disease treatments [1][2][6]. Group 3: Medicinal Value of Antarctic Krill - Antarctic krill oil has shown potential benefits in metabolic regulation, cardiovascular protection, bone health maintenance, neuroprotection, and immune enhancement, making it a sought-after product in the health sector [3][6]. - The unique physiological characteristics of Antarctic krill, derived from their extreme living conditions, contribute to their rich nutritional profile, which includes omega-3 fatty acids and antioxidants, making them valuable for drug development [6][7]. - The global marine biopharmaceutical industry is experiencing growth, with the demand for marine biopharmaceuticals in China exceeding 2.5 million tons in 2022 and projected to surpass 3 million tons by 2024 [7][8]. Group 4: Research and Development Advances - Significant breakthroughs have been made in the research of Antarctic krill, with studies indicating its potential in anti-aging, cancer treatment, and cardiovascular disease management, with some findings already entering preclinical or early clinical trial stages [9][10][11]. - The application of new technologies in drug delivery systems using krill-derived compounds is enhancing the efficacy of existing medications and reducing development costs [8][12]. - The development of krill-based drugs is positioned to fill clinical gaps and enhance China's competitiveness in high-end formulations and peptide drugs [7][9].